NCT03776500View on ClinicalTrials.gov

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PBTZ169 in Multiple Dosing

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

February 21, 2019

Primary Completion Date

March 20, 2020

Study Completion Date

March 20, 2020

Conditions
Tuberculosis, Pulmonary
Interventions
DRUG

PBTZ169

PBTZ169 crystalline supplied as powder for oral solution

DRUG

Placebo

matching placebo supplied as powder for oral solution

Trial Locations (1)

1011

Division of Clinical Pharmacology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne

All Listed Sponsors
collaborator

Bill and Melinda Gates Foundation

OTHER

lead

Innovative Medicines for Tuberculosis

OTHER

NCT03776500 - Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PBTZ169 in Multiple Dosing | Biotech Hunter | Biotech Hunter